

Financial Tear Sheet

Corporate Profile

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. Its lead asset, immuno-oncology agent Plinabulin, is currently in multiple global registration studies, for the prevention of chemotherapy-induced neutropenia and as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company also has a robust internal early-stage pipeline, and a research collaboration with Fred Hutchinson Cancer Research Center and University of Washington exploring the ubiquitin ligase protein to target and promote the destruction of disease causing proteins, such as oncogenes.

Led by a highly qualified management team with proven pharmaceutical experience and a combined 30+ drugs brought to market, and a unique, highly scalable business model that integrates clinical resources in the U.S. and China, BeyondSpring believes that it is well positioned for expeditious progress towards regulatory approvals and commercialization in a cost-efficient manner.

Investors

Primary IR

Contact


Steve Silver
 KCSA Strategic
 Communications
Phone: 212.896.1220
E-mail: ssilver@kcsa.com

Jeffrey Goldberger
 KCSA Strategic
 Communications
Phone: 212.896.1249
E-mail: jgoldberger@kcsa.com

Stock Information

BYSI (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$25.90
Change (%)	▼ 0.35 (1.33%)
Volume	2,163
52 Week Low	\$16.55
Market Cap	\$443,090,235
Rolling EPS	-4.45
PE Ratio	0
Shares Outstanding	16,879,628



Recent Press Releases & Upcoming Events

February 7, 2018

[BeyondSpring to Present at Upcoming Investor Conferences](#)

February 5, 2018

[BeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia](#)

January 26, 2018

[BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
February 21, 2018	6-K
February 14, 2018	SC 13G
February 14, 2018	SC 13G
February 14, 2018	SC 13G

Corporate Governance

Lan Huang, Ph.D.	Co-founder, Chairman & CEO
Ramon Mohanlal, M.D., Ph.D.	Chief Medical Officer
Richard A. Brand, M.B.A.	Chief Financial Officer
G. Kenneth Lloyd, Ph.D.	Chief Scientific Officer
Gordon L. Schooley, Ph.D.	Chief Regulatory Officer